Clinical trial NCT02412462: Phase I Dose Escalation Study of AB-16B5 in Subjects With an Advanced Solid Malignancy
Official title: A Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AB-16B5 in Subjects With an Advanced Solid Malignancy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Solid Tumor
Metastatic Cancer
Keywords: Phase I
Clusterin
Epithelial-to-Mesenchymal Transition (EMT)
Circulating Tumor Cells (CTC)
EMT and Stem Cell Biomarkers
Pharmacokinetics
Lead sponsor: Alethia Biotherapeutics
Sponsor class: INDUSTRY
First posted: 2015-04-09
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a Phase 1 clinical study to investigate the safety, pharmacokinetics and pharmacodynamics of AB-16B5 in patients with an advanced solid malignancy. AB-16B5 is a humanized monoclonal antibody that inhibits the activity of the secreted form of clusterin (sCLU), a potent inducer of the epithelial-to-mesenchymal transition (EMT). Eligible subjects will have a disease that has been refractory to prior therapy and is unlikely to benefit from known therapies.


Eligibility criteria: Inclusion Criteria:

* Subjects with a histologically or cytologically confirmed advanced solid malignancy that has been refractory to prior therapy and is unlikely to benefit from known therapies.
* Subjects may have measurable or non-measurable but evaluable disease.
* Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2 and an estimated life expectancy of at least 12 weeks.
* Subjects must be ≥ 18 years old.
* Male, or female subjects who are post-menopausal (amenorrheic for at least 12 months), or surgically or biologically sterile. Females of childbearing potential with a negative serum pregnancy test prior to entering the study and using adequate forms of contraception for the duration of the study, including 30 days after the last treatment. Males should avoid fathering children during the course of the study, and adequate methods of contraception should be used by both male and female subjects. Subjects and their partners with reproductive potential must use an effective contraceptive method while the subject is on the study treatment and for 30 days after the last treatment.
* Subjects must have adequate organ and immune function as indicated by the following laboratory values:

  * ANC ≥ 1.5 X 109/L
  * Platelets \> 100 X 109/L
  * Hemoglobin ≥ 90 g/L
  * Serum creatinine ≤ 132 µmol/L
  * Total Bilirubin ≤ 1.5 X ULN
  * AST (SGOT) and ALT (SGPT) ≤ 3 X ULN\* or;

    * 5 X ULN\* (if hepatic metastases present)

      * ULN: Institution's upper limit of normal
* Subjects enrolled in the standard dose escalation portion of the study must have a tumor lesion amenable for biopsy with no contraindications for biopsy.
* Subjects must understand and be able and willing and likely to fully comply with the study procedures, including scheduled follow-up, and restrictions.
* Subjects must have given written personally signed and dated informed consent to participate in the study, in accordance with the International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) Guidelines, before completing any study related procedures.

Exclusion Criteria:

* Subjects with medical, social, or psychosocial factors that, in the opinion of the Investigator, could impact safety or compliance with study procedures.
* Prior cancer therapy including surgery, radiotherapy, chemotherapy, hormonal and biological therapies within 3 weeks prior to study treatment.
* Uncontrolled brain metastases.
* Uncontrolled infection.
* Clinically significant ECG abnormalities.
* Known hypersensitivity of Grade \> 2 to previous monoclonal antibody therapy.
* History of alcohol or other substance abuse within the last year.
* Use of another investigational agent in a clinical trial within the last 4 weeks prior to study treatment.
* Female subjects who are pregnant or lactating, including females with a positive pregnancy test at screening must be excluded.

Primary outcomes:
measure: Number of participants with an adverse event as a measure of safety and tolerability
timeFrame: Up to treatment discontinuation + 30 days with an estimated treatment duration of 6 to 24 weeks
Secondary outcomes:
measure: Determination of plasma concentrations of AB-16B5
timeFrame: Several time-points during Cycle 1 and Cycle 2 for a total of 6 weeks
measure: Objective tumor responses in subjects with measurable disease according to RECIST
timeFrame: Up to treatment discontinuation + 30 days with an estimated treatment duration of 6 to 24 weeks
measure: Monitoring of epithelial-to-mesenchymal (EMT) and stem cells biomarkers in peripheral blood circulating tumor cells and paired tumor biopsies
timeFrame: Up to treatment discontinuation + 30 days with an estimated treatment duration of 6 to 24 weeks
Other outcomes:
Locations:
city: Montreal
country: Canada
facility: Jewish General Hospital
state: Quebec
Study officials:
References: